Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Public ClinicalTrials.gov record NCT02952508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.
Study identification
- NCT ID
- NCT02952508
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Iopofosine I 131 single dose Drug
- Iopofosine I 131 multiple dose Drug
- Iopofosine I 131 fractionated dose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 26, 2017 (Actual)
- Primary completion
- Jun 22, 2026 (Estimated)
- Completion
- Dec 22, 2027 (Estimated)
- Last update posted
- Mar 18, 2026
2017 – 2027
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cellectar Biosciences site | Los Angeles | California | 90095 | — |
| Cellectar Biosciences site | Redlands | California | 92373 | — |
| Cellectar Biosciences site | Washington D.C. | District of Columbia | 20007 | — |
| Cellectar Biosciences site | Jacksonville | Florida | 32224 | — |
| Cellectar Biosciences site | Miami | Florida | 33165 | — |
| Cellectar Biosciences site | Tampa | Florida | 33612 | — |
| Cellectar Biosciences | Atlanta | Georgia | 30332 | — |
| Cellectar Biosciences site | Maywood | Illinois | 60153 | — |
| Cellectar Biosciences site | Warrenville | Illinois | 60555 | — |
| Cellectar Biosciences site | Westwood | Kansas | 66205 | — |
| Cellectar Biosciences site | New Orleans | Louisiana | 70121 | — |
| Cellectar Biosciences site | Baltimore | Maryland | 21287 | — |
| Cellectar Biosciences | Bethesda | Maryland | 20817 | — |
| Cellectar Biosciences site | Boston | Massachusetts | 02215 | — |
| Cellectar Biosciences | North Bergen | New Jersey | 07047 | — |
| Cellectar Biosciences site | Buffalo | New York | 14263 | — |
| Cellectar Biosciences site | New York | New York | 10065 | — |
| Cellectar Biosciences site | Rochester | New York | 14642 | — |
| Cellectar Biosciences site | Durham | North Carolina | 27705 | — |
| Cellectar Biosciences | Canton | Ohio | 44718 | — |
| Cellectar Biosciences site | Cincinnati | Ohio | 45219 | — |
| Cellectar Biosciences Site | Charleston | South Carolina | 29425 | — |
| Cellectar Biosciences | Greenville | South Carolina | 29605 | — |
| Cellectar Biosciences site | Knoxville | Tennessee | 37920 | — |
| Cellectar Biosciences site | Dallas | Texas | 75246 | — |
| Cellectar Biosciences site | Dallas | Texas | 75390 | — |
| Cellectar Biosciences site | Houston | Texas | 77030 | — |
| Cellectar Biosciences site | Seattle | Washington | 98109 | — |
| Cellectar Biosciences site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02952508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02952508 live on ClinicalTrials.gov.